Cost of Illness in Inflammatory Bowel Disease
| العنوان: | Cost of Illness in Inflammatory Bowel Disease |
|---|---|
| المؤلفون: | C. Ganesh Pai, Nagesh Kamat, Asha Kamath, M. Surulivel Rajan |
| المصدر: | Digestive Diseases and Sciences. 62:2318-2326 |
| بيانات النشر: | Springer Science and Business Media LLC, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Adolescent, Physiology, Total cost, India, Disease, Gastroenterology, Inflammatory bowel disease, Young Adult, 03 medical and health sciences, Pharmacoeconomics, Indirect costs, 0302 clinical medicine, Cost of Illness, Internal medicine, medicine, Humans, Prospective Studies, health care economics and organizations, Aged, business.industry, Middle Aged, Hepatology, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, Observational study, business, Follow-Up Studies |
| الوصف: | Frequent relapses sometimes necessitating hospitalization and the absence of pharmacological cure contribute to substantial healthcare costs in inflammatory bowel diseases (IBDs). The costs of health care in Indian patients with IBD are unknown. To evaluate the annual costs for treating Crohn’s disease and ulcerative colitis. A prevalence-based, micro-costing method was used to assess the components of annual costs in a prospective, observational study conducted in a tertiary healthcare center enrolled over a 24-month period beginning of July 2014. At enrollment, 43/59 (72.88%) patients with UC and 18/25 (72%) with CD were in remission. The annual median (IQR) cost per UC and CD patient in remission was INR 43,140 (34,357–51,031) [USD $707 (563–836)] and INR 43,763.5 (32,202–57,372) [USD $717 (527–940)], respectively, and in active disease was INR 52,436.5 (49,229–67,567.75) [$859 (807–1107)] and INR 72,145 (49,447–92,212) [USD $1182 (811–1512)], respectively. Compared with remission, active disease had a 1.4-fold higher cost for CD as compared to UC. In both groups, the greatest component of direct costs was drugs. Thirteen (22%) and 7 (28%) patients with UC and CD needed hospitalization accounting for 23.1 and 20.4% of the total costs, respectively. At one year, direct costs surmounted indirect costs in UC and CD (p |
| تدمد: | 1573-2568 0163-2116 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb996f5637ddff4031ff592b54607b21 https://doi.org/10.1007/s10620-017-4690-z |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....fb996f5637ddff4031ff592b54607b21 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 15732568 01632116 |
|---|